{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:riociguat",
  "owner": "cardio",
  "kind": "drug",
  "slug": "riociguat",
  "name": "Riociguat",
  "aliases": [
    "ADEMPAS"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Riociguat, sold as Adempas, is a soluble guanylate cyclase stimulator. The US label lists two uses in adults: persistent or recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment, or inoperable disease, and pulmonary arterial hypertension (WHO Group 1), in both to improve exercise capacity. The label carries a boxed warning for embryo-fetal toxicity: it says the medicine is contraindicated during pregnancy because it may cause fetal harm. That risk concerns the unborn child and is recorded separately.",
  "summary_technical": "RxNorm ingredient 1439816; UNII RU3FE2Y4XI. MeSH has no descriptor for riociguat (an exact-label lookup returned an empty list on 2026-11-18), so the record carries no MeSH code. RxClass lists the FDA established pharmacologic class Soluble Guanylate Cyclase Stimulator, so the record is filed under the class page. The label read is the Bayer HealthCare Pharmaceuticals Inc. label for Adempas, application NDA204819 (approved 2013-10-08 as a new molecular entity in Drugs@FDA), effective 2026-08-13 in openFDA. Chronic thromboembolic pulmonary hypertension has no page of its own in the atlas, so that indication links to the pulmonary hypertension page. The adult indications and the boxed warning (recipient: fetal) sit in separate claims and contexts. This page records label indications, the boxed-warning title and one sentence, the mechanism sentence and the class only: no trial result and no dose is given.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-18",
  "last_evidence_check": "2026-11-18",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "rxnorm",
      "value": "1439816",
      "normalized_value": "1439816",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "unii",
      "value": "RU3FE2Y4XI",
      "normalized_value": "RU3FE2Y4XI",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "blood-vessels",
        "heart"
      ],
      "condition-area": [
        "coronary-and-vascular-disease"
      ]
    }
  },
  "payload": {
    "level": "substance",
    "mechanism": "The label says riociguat stimulates soluble guanylate cyclase, an enzyme in the cardiopulmonary system and the receptor for nitric oxide, and that it both sensitizes the enzyme to nitric oxide and stimulates it directly."
  },
  "content_digest": "33a4b24de03dc32a1de996a643b59b869214ae1059dae7ca7fcba6a991ba92e4",
  "review": {
    "content_digest": "33a4b24de03dc32a1de996a643b59b869214ae1059dae7ca7fcba6a991ba92e4",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-adempas-label-fetal-warning",
      "owner": "cardio",
      "subject_entity_id": "cardio:riociguat",
      "category": "safety",
      "statement": "The same US label of Adempas carries a boxed warning titled embryo-fetal toxicity. It says the medicine is contraindicated for use during pregnancy because it may cause fetal harm, based on animal data.",
      "context": {
        "id": "cardio:ctx-fda-adempas-label-fetal-risk",
        "label": "The developing fetus, for a person taking riociguat during pregnancy, as described in a US label boxed warning",
        "recipient": "fetal",
        "population": "The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Fetus during pregnancy; the passage read gives no gestational ages",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine."
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records the boxed-warning statement named above only. The warning also tells prescribers what to do before and during treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the label read, NDA204819.",
          "snapshot": {
            "id": "cardio:openfda-label-adempas-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:35Z",
            "content_hash": "4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f",
            "source_effective_date": "2026-08-13",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-adempas",
            "source_type": "regulator",
            "title": "openFDA drug label record for Adempas (riociguat tablets), Bayer HealthCare Pharmaceuticals Inc. label: indications, boxed warning and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%227b57509a-3d5d-41d4-8fed-1471e26372a3%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 7b57509a-3d5d-41d4-8fed-1471e26372a3 (manufacturer Bayer HealthCare Pharmaceuticals Inc., application NDA204819), returned on 2026-11-18. The label text is dated 2026-08-13 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-adempas.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20260813.",
          "snapshot": {
            "id": "cardio:openfda-label-adempas-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:35Z",
            "content_hash": "4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f",
            "source_effective_date": "2026-08-13",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-adempas",
            "source_type": "regulator",
            "title": "openFDA drug label record for Adempas (riociguat tablets), Bayer HealthCare Pharmaceuticals Inc. label: indications, boxed warning and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%227b57509a-3d5d-41d4-8fed-1471e26372a3%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 7b57509a-3d5d-41d4-8fed-1471e26372a3 (manufacturer Bayer HealthCare Pharmaceuticals Inc., application NDA204819), returned on 2026-11-18. The label text is dated 2026-08-13 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-adempas.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].boxed_warning[0], title",
          "applicability_note": "Label passage quoted in the research quote table (Q-K29-ADE-LB-07).",
          "snapshot": {
            "id": "cardio:openfda-label-adempas-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:35Z",
            "content_hash": "4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f",
            "source_effective_date": "2026-08-13",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-adempas",
            "source_type": "regulator",
            "title": "openFDA drug label record for Adempas (riociguat tablets), Bayer HealthCare Pharmaceuticals Inc. label: indications, boxed warning and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%227b57509a-3d5d-41d4-8fed-1471e26372a3%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 7b57509a-3d5d-41d4-8fed-1471e26372a3 (manufacturer Bayer HealthCare Pharmaceuticals Inc., application NDA204819), returned on 2026-11-18. The label text is dated 2026-08-13 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-adempas.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].boxed_warning[0], first paragraph",
          "applicability_note": "Label passage quoted in the research quote table (Q-K29-ADE-LB-08).",
          "snapshot": {
            "id": "cardio:openfda-label-adempas-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:35Z",
            "content_hash": "4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f",
            "source_effective_date": "2026-08-13",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-adempas",
            "source_type": "regulator",
            "title": "openFDA drug label record for Adempas (riociguat tablets), Bayer HealthCare Pharmaceuticals Inc. label: indications, boxed warning and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%227b57509a-3d5d-41d4-8fed-1471e26372a3%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 7b57509a-3d5d-41d4-8fed-1471e26372a3 (manufacturer Bayer HealthCare Pharmaceuticals Inc., application NDA204819), returned on 2026-11-18. The label text is dated 2026-08-13 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-adempas.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "b7e8f9fd69dab63eec2670171323dbd48149c2afe85251e7723c91fe3a2ac5f5",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-adempas-label-fetal-warning.json"
    },
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-adempas-label-indications",
      "owner": "cardio",
      "subject_entity_id": "cardio:riociguat",
      "category": "descriptive",
      "statement": "The US label of Adempas (riociguat tablets, Bayer HealthCare Pharmaceuticals Inc., application NDA204819; the version dated 2026-08-13 in openFDA) describes riociguat as a soluble guanylate cyclase stimulator. It lists treating adults with persistent or recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) after surgical treatment, or inoperable disease, and adults with pulmonary arterial hypertension (WHO Group 1), to improve exercise capacity.",
      "context": {
        "id": "cardio:ctx-fda-adempas-label-us",
        "label": "Adults with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension, as described in the US label of Adempas",
        "recipient": "adult",
        "population": "Adults with persistent or recurrent chronic thromboembolic pulmonary hypertension after surgical treatment, or inoperable disease (WHO Group 4), and adults with pulmonary arterial hypertension (WHO Group 1), as the label states.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Adults, as the label states",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Adults with persistent or recurrent chronic thromboembolic pulmonary hypertension after surgical treatment, or inoperable disease (WHO Group 4), and adults with pulmonary arterial hypertension (WHO Group 1), as the label states."
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. The label also lists improving WHO functional class and delaying clinical worsening; only the exercise capacity wording is quoted here.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "context",
          "locator": "results[0].openfda.application_number[0]",
          "applicability_note": "Application number of the label read, NDA204819.",
          "snapshot": {
            "id": "cardio:openfda-label-adempas-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:35Z",
            "content_hash": "4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f",
            "source_effective_date": "2026-08-13",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-adempas",
            "source_type": "regulator",
            "title": "openFDA drug label record for Adempas (riociguat tablets), Bayer HealthCare Pharmaceuticals Inc. label: indications, boxed warning and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%227b57509a-3d5d-41d4-8fed-1471e26372a3%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 7b57509a-3d5d-41d4-8fed-1471e26372a3 (manufacturer Bayer HealthCare Pharmaceuticals Inc., application NDA204819), returned on 2026-11-18. The label text is dated 2026-08-13 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-adempas.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20260813.",
          "snapshot": {
            "id": "cardio:openfda-label-adempas-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:35Z",
            "content_hash": "4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f",
            "source_effective_date": "2026-08-13",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-adempas",
            "source_type": "regulator",
            "title": "openFDA drug label record for Adempas (riociguat tablets), Bayer HealthCare Pharmaceuticals Inc. label: indications, boxed warning and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%227b57509a-3d5d-41d4-8fed-1471e26372a3%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 7b57509a-3d5d-41d4-8fed-1471e26372a3 (manufacturer Bayer HealthCare Pharmaceuticals Inc., application NDA204819), returned on 2026-11-18. The label text is dated 2026-08-13 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-adempas.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE",
          "applicability_note": "Label passage quoted in the research quote table (Q-K29-ADE-LB-04, Q-K29-ADE-LB-05, Q-K29-ADE-LB-06).",
          "snapshot": {
            "id": "cardio:openfda-label-adempas-2026-11-18",
            "retrieved_at": "2026-11-18T22:01:35Z",
            "content_hash": "4929dc68f3f2942311918cd67714bfda8f62ee2cbca16ca7e941b7e34285fc6f",
            "source_effective_date": "2026-08-13",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-adempas",
            "source_type": "regulator",
            "title": "openFDA drug label record for Adempas (riociguat tablets), Bayer HealthCare Pharmaceuticals Inc. label: indications, boxed warning and mechanism",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%227b57509a-3d5d-41d4-8fed-1471e26372a3%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 7b57509a-3d5d-41d4-8fed-1471e26372a3 (manufacturer Bayer HealthCare Pharmaceuticals Inc., application NDA204819), returned on 2026-11-18. The label text is dated 2026-08-13 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/k29-openfda-label-adempas.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "488f8afa182cc3ffefd8419fc9039912dc6aff87c0c4c4c4a6092dfb0c54d531",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-adempas-label-indications.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "subtype_of",
        "label": "Riociguat is a soluble guanylate cyclase stimulator (FDA established pharmacologic class in RxClass)",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:soluble-guanylate-cyclase-stimulators",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-1439816-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[1].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists pulmonary arterial hypertension (WHO Group 1) in adults, to improve exercise capacity, as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:pulmonary-arterial-hypertension",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-adempas-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists persistent or recurrent chronic thromboembolic pulmonary hypertension (WHO Group 4) in adults, after surgical treatment or when inoperable, as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:pulmonary-hypertension",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-adempas-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": []
  },
  "page_path": "drugs/riociguat/",
  "context_path": "api/v1/context/cardio--riociguat.md"
}
